Investigation of dermatology life quality index and serum prolactin and serum dehydroepiandrosterone sulphate levels in patients with chronic urticaria

Basit Öğe Kaydı
dc.contributor.authorUcmak, Derya
dc.contributor.authorAkkurt, Meltem
dc.contributor.authorUcmak, Feyzullah
dc.contributor.authorToprak, Gulten
dc.contributor.authorAcar, Gurbet
dc.contributor.authorArica, Mustafa
dc.date.accessioned2024-04-24T17:37:34Z
dc.date.available2024-04-24T17:37:34Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Chronic urticaria (CU) is known to be one of the most disturbing diseases which significantly affect the quality of life. Prolactin (PRL) and DHEA-S (dehydroepiandrosterone sulfate) are stress-associated hormones in chronic urticaria. Objective: In the present study, we measured DHEA-S and prolactin levels of CU patients, compared them with healthy subjects and evaluated the association between disease status and serum levels. Methods: Plasma DHEA-S and serum PRL concentrations were measured in 48 CU patients and 31 healthy subjects. CU activity was assessed with the use of the symptom scores recommended with EAACI/GALEN/EDF guidelines. All the patients participating in this study were evaluated by means of Dermatology Life Quality Index (DLQI). With respect to DLQI and clinical activity scores, plasma DHEA-S and serum prolactin levels were compared. Results: Median plasma concentration of DHEA-S was significantly lower in CU patients as compared with healthy subjects (p = 0.026). DHEA-S levels of females were significantly lower than males (p = 0.001). Mean PRL values of the patients were higher than the controls, but not statistically significant (p = 0.619) and there was a statistically signifcant inverse correlation with DHEA-S levels (p = 0.04, r = -0.298). There was a significant correlation between DLQI and clinical disease activity (p < 0.001, r = 0.748). Conclusions: The exact relation of hormones to CU pathogenesis remains to be determined by further clinical studies. In addition, therapies aiming to increase DHEA-S and decrease PRL may be subject to trial in CU.en_US
dc.identifier.endpage299en_US
dc.identifier.issn0125-877X
dc.identifier.issn2228-8694
dc.identifier.issue4en_US
dc.identifier.pmid25543039
dc.identifier.scopus2-s2.0-84919880159
dc.identifier.scopusqualityQ1
dc.identifier.startpage293en_US
dc.identifier.urihttps://hdl.handle.net/11468/21030
dc.identifier.volume32en_US
dc.identifier.wosWOS:000348096500004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAllergy Immunol Soc Thailand,en_US
dc.relation.ispartofAsian Pacific Journal of Allergy and Immunology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Urticariaen_US
dc.subjectDehydroepiandrosterone-Sulphateen_US
dc.subjectLife Quality Indexen_US
dc.subjectProlactinen_US
dc.subjectClinical Disease Activityen_US
dc.titleInvestigation of dermatology life quality index and serum prolactin and serum dehydroepiandrosterone sulphate levels in patients with chronic urticariaen_US
dc.titleInvestigation of dermatology life quality index and serum prolactin and serum dehydroepiandrosterone sulphate levels in patients with chronic urticaria
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu